Literature DB >> 16474785

The current status of laparoscopic retroperitoneal lymph node dissection for non-seminomatous germ-cell tumors.

Brett S Carver1, Joel Sheinfeld.   

Abstract

An appropriately performed retroperitoneal lymph node dissection (RPLND) is both a diagnostic and a therapeutic procedure in the management of non-seminomatous germ-cell tumors. In an attempt to minimize the morbidity associated with an open RPLND, several investigators have evaluated the role of laparoscopic RPLND. Laparoscopic RPLND is technically feasible in the hands of dedicated experts, and results in a reduced hospital stay, operative blood loss, and post-operative morbidity compared to open RPLND. Currently, however, none of the reports in the literature have adequately evaluated the therapeutic efficacy of laparoscopic RPLND, as the vast majority of patients are treated with adjuvant chemotherapy regardless of the risk of systemic relapse. Future prospective internal review board-approved trials need to be developed to evaluate the therapeutic efficacy of laparoscopic RPLND, with careful observation of patients with pathologic low-volume nodal disease.

Entities:  

Mesh:

Year:  2005        PMID: 16474785     DOI: 10.1038/ncpuro0226

Source DB:  PubMed          Journal:  Nat Clin Pract Urol        ISSN: 1743-4270


  3 in total

Review 1.  Critical evaluation of modified templates and current trends in retroperitoneal lymph node dissection.

Authors:  Shane Pearce; Zoe Steinberg; Scott Eggener
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

2.  Diagnostic laparoscopic biopsy for intraabdominal tumors.

Authors:  Yasuo Sakamoto; Ryuichi Karashima; Satoshi Ida; Yu Imamura; Shiro Iwagami; Yoshifumi Baba; Yuji Miyamoto; Naoya Yoshida; Hideo Baba
Journal:  Surg Today       Date:  2014-09-12       Impact factor: 2.549

Review 3.  Complications of laparoscopic retroperitoneal lymph node dissection in testicular cancer.

Authors:  Patrick A Kenney; Ingolf A Tuerk
Journal:  World J Urol       Date:  2008-07-02       Impact factor: 4.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.